Physician profile
Tammy Lo
NPI 1740595792
$4,944.34
in general payments reported to CMS, 2019-2025
41 companies · $1,286 in 2025
The $1,286 reported for 2025 was more than what 90% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $620 · 2023: $894 · 2024: $1,997 · 2025: $1,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,177.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $462.48 | 2023-2025 | |
| Celgene Corporation | $462.38 | 2022-2025 | Pomalyst, Reblozyl, Opdivo |
| Rigel Pharmaceuticals, INC. | $379.39 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| E.R. Squibb & Sons, L.L.C. | $329.54 | 2021-2025 | Opdualag, Opdivo, Krazati |
| Novartis Pharmaceuticals Corporation | $325.49 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $318.49 | 2021-2025 | Enhertu, Tagrisso, Calquence |
| Eisai INC. | $229.43 | 2022-2025 | |
| Janssen Biotech, INC. | $229.36 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Astellas Pharma US INC | $207.57 | 2022-2024 | Xospata, Padcev |
| Array Biopharma INC | $176.79 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Genentech USA, INC. | $173.34 | 2023-2025 | Venclexta, Tecentriq, Alecensa |
| Regeneron Healthcare Solutions, INC. | $156.86 | 2022-2025 | Libtayo |
| Incyte Corporation | $131.38 | 2022-2025 | Jakafi, Pemazyre, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $117.51 | 2022-2025 | Ninlaro, Alunbrig |
| Mirati Therapeutics, INC. | $105.56 | 2023-2024 | Krazati |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.